{"filing":{"accession_number":"0001193125-26-357258","cik":"0001534133","ticker":"CALC","company_name":"CalciMedica, Inc.","form":"8-K","filing_date":"2026-08-19","report_date":"2026-08-19","primary_document":"d434771d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1534133/000119312526357258/d434771d8k.htm"},"events":[{"id":28632,"run_id":26200,"accession_number":"0001193125-26-357258","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"CalciMedica held its Annual Meeting on July 23, 2026, and shareholders voted on eight proposals including director elections, auditor ratification, an equity plan amendment increasing authorized shares by 7.5 million, say-on-pay votes, a reverse stock split, and two material warrant issuances involving up to approximately 37.3 million shares of potential dilution.","company_name":"CalciMedica, Inc.","ticker":"CALC","filing_date":"2026-08-19","form":"8-K","submitted_at":null,"items":[{"id":30638,"accession_number":"0001193125-26-357258","item_number":"5.02","item_title":null,"event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The disclosure reports stockholder approval of an amendment to the 2023 Equity Incentive Plan that increases authorized shares by 7.5 million and modifies the calculation of automatic share reserve increases. This is a compensatory arrangement amendment affecting equity grants and incentive plan mechanics, which falls squarely within Item 5.02(e) and the exec_compensation category. The material increase in share authorization and plan modifications would affect investor assessment of dilution and executive compensation capacity.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-20T10:02:57.045147+00:00","company_name":"","ticker":null,"filing_date":""},{"id":30639,"accession_number":"0001193125-26-357258","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a classic Item 5.07 disclosure of shareholder vote results from CalciMedica's Annual Meeting held on July 23, 2026. The filing reports voting outcomes on eight proposals including director elections (Proposal 1), auditor ratification (Proposal 2), equity plan amendment (Proposal 3), say-on-pay votes (Proposals 4–5), reverse stock split approval (Proposal 6), and two material warrant issuances under Nasdaq rules (Proposals 7–8). The warrant issuances are particularly material, involving up to ~37.3 million shares of dilution. All results are presented with vote counts and broker non-votes as required by SEC rules.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-20T10:02:57.045147+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":30638,"accession_number":"0001193125-26-357258","item_number":"5.02","item_title":null,"event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The disclosure reports stockholder approval of an amendment to the 2023 Equity Incentive Plan that increases authorized shares by 7.5 million and modifies the calculation of automatic share reserve increases. This is a compensatory arrangement amendment affecting equity grants and incentive plan mechanics, which falls squarely within Item 5.02(e) and the exec_compensation category. The material increase in share authorization and plan modifications would affect investor assessment of dilution and executive compensation capacity.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-20T10:02:57.045147+00:00","company_name":"CalciMedica, Inc.","ticker":"CALC","filing_date":"2026-08-19"},{"id":30639,"accession_number":"0001193125-26-357258","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a classic Item 5.07 disclosure of shareholder vote results from CalciMedica's Annual Meeting held on July 23, 2026. The filing reports voting outcomes on eight proposals including director elections (Proposal 1), auditor ratification (Proposal 2), equity plan amendment (Proposal 3), say-on-pay votes (Proposals 4–5), reverse stock split approval (Proposal 6), and two material warrant issuances under Nasdaq rules (Proposals 7–8). The warrant issuances are particularly material, involving up to ~37.3 million shares of dilution. All results are presented with vote counts and broker non-votes as required by SEC rules.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-20T10:02:57.045147+00:00","company_name":"CalciMedica, Inc.","ticker":"CALC","filing_date":"2026-08-19"}]}